Literature DB >> 25398292

Ki-67 proliferation index in patients with placenta previa percreta in the third trimester.

Nese Hilali1, Sezen Kocarslan, Mehmet Vural, Adnan Incebiyik, Aysun Camuzcuoglu, Hakan Camuzcuoglu.   

Abstract

AIM: The purpose of this study was to investigate proliferative capacity of placenta previa percreta in the third trimester via evaluating Ki-67 proliferating index.
METHODS: The paraffin blocks of placental tissues, which were obtained from the patients who underwent hysterectomy for placenta previa percreta (n = 12, gestational age > 28 weeks), from legal abortions (n = 12, gestational age < 10 weeks), and of cesarean deliveries with the indication of previous cesarean section, without any complication (n = 12, gestational age > 38 weeks), between January 2011 and April 2013, were included into the study. The paraffin blocks of the patients were stained with Ki-67 (proliferating cell marker) immunohistochemically, and Ki-67 proliferation index levels were calculated.
RESULTS: Ki-67 proliferation index levels were higher in patients with legal abortions than patients with placenta percreta or noncomplicated cesarean delivery group. However, any statistically significant difference was not detected between the percreta and noncomplicated groups (p > 0.05).
CONCLUSION: The tissue samples of the patients with placenta previa percreta exhibited low proliferative capacity similar to the samples of normal placentation group.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25398292     DOI: 10.1007/s00508-014-0634-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  18 in total

Review 1.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

2.  Maternal outcome after conservative treatment of placenta accreta.

Authors:  Loïc Sentilhes; Clémence Ambroselli; Gilles Kayem; Magali Provansal; Hervé Fernandez; Franck Perrotin; Norbert Winer; Fabrice Pierre; Alexandra Benachi; Michel Dreyfus; Estelle Bauville; Dominique Mahieu-Caputo; Loïc Marpeau; Philippe Descamps; François Goffinet; Florence Bretelle
Journal:  Obstet Gynecol       Date:  2010-03       Impact factor: 7.661

3.  Arteriovenous malformation identification after conservative management of placenta percreta with uterine artery embolization and adjunctive therapy.

Authors:  James T Barber; Terry B Tressler; Gregory S Willis; Francis J Martinez; David B Peisner; Jay D Goodman; Claudia D Taboada
Journal:  Am J Obstet Gynecol       Date:  2011-02-24       Impact factor: 8.661

4.  Abnormal placentation: twenty-year analysis.

Authors:  Serena Wu; Masha Kocherginsky; Judith U Hibbard
Journal:  Am J Obstet Gynecol       Date:  2005-05       Impact factor: 8.661

5.  Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.

Authors:  Zahoor Qadir Samra; Snober Ahmad; Mehwish Javeid; Nadia Dar; Muhammad Shahbaz Aslam; Iram Gull; Mubashar Mustaneer Ahmad
Journal:  Prep Biochem Biotechnol       Date:  2013       Impact factor: 2.162

6.  Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast.

Authors:  P Tantbirojn; C P Crum; M M Parast
Journal:  Placenta       Date:  2008-06-02       Impact factor: 3.481

Review 7.  Conservative management of morbidly adherant placenta - a case report and review of literature.

Authors:  Muntaha Khan; P Sachdeva; R Arora; S Bhasin
Journal:  Placenta       Date:  2013-08-12       Impact factor: 3.481

8.  Occult placenta accreta: the missing link in the diagnosis of abnormal placentation.

Authors:  Jerzy Stanek; Zarius Drummond
Journal:  Pediatr Dev Pathol       Date:  2007 Jul-Aug

9.  Log-linear human chorionic gonadotropin elimination in cases of retained placenta percreta.

Authors:  Michael L Stitely; M Gerard Jackson; William H Holls
Journal:  Arch Gynecol Obstet       Date:  2013-07-11       Impact factor: 2.344

10.  The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review.

Authors:  Monika M Skubisz; Stephen Tong
Journal:  ISRN Obstet Gynecol       Date:  2012-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.